Bio-chemical markers of chronic, non-infectious disease in the human tear film

References

• Willcox MDP, Argueso P, Georgiev GA, et al. TFOS DEWS II tear film report. Ocul Surf. 2017;15:366–403.
   PubMed Web of Science ®Google Scholar
• Postnikoff CK, Held K, Viswanath V, et al. Enhanced closed eye neutrophil degranulation in dry eye disease. Ocul Surf. 2020;18:841–851.
   Web of Science ®Google Scholar
• Kenny A, Jiménez-Mateos EM, Zea-Sevilla MA, et al. Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer’s disease. Sci Rep. 2019;9:15437.
   Web of Science ®Google Scholar
• Markoulli M, Papas E, Petznick A, et al. Validation of the flush method as an alternative to basal or reflex tear collection. Curr Eye Res. 2011;36:198–207.
   PubMed Web of Science ®Google Scholar
• Markoulli M, Gokhale M, You J. Substance P in flush tears and schirmer strips of healthy participants. Optometry Vision Sci. 2017;94:527–533.
   Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
   Web of Science ®Google Scholar
• Amur S. Biomarker technology: speaking the same language. cited 2021 Jul 8th. Available from: https://www.fda.gov/media/102547/download
   Google Scholar
• Green-Church KB, Nichols KK, Kleinholz NM, et al. Investigation of the human tear film proteome using multiple proteomic approaches. Mol Vis. 2008;14:456–470.
   PubMed Web of Science ®Google Scholar
• Markoulli M, Papas E, Cole N, et al. The diurnal variation of matrix metalloproteinase-9 and its associated factors in human tears. Invest Ophthalmol Vis Sci. 2012;53:1479–1484.
   PubMed Web of Science ®Google Scholar
• Markoulli M, Papas E, Cole N, et al. Effect of contact lens wear on the diurnal profile of matrix metalloproteinase 9 in tears. Optom Vis Sci. 2013;90:419–429.
   Web of Science ®Google Scholar
• Sapra A BP. Diabetes Mellitus. 2020
   Google Scholar
• Duby JJ, Campbell RK, Setter SM, et al. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 2004;61:160-173; quiz 175-166.
   PubMed Web of Science ®Google Scholar
• Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44:260–277.
   PubMed Web of Science ®Google Scholar
• Furuichi K, Shimizu M, Okada H, et al. Clinico-pathological features of kidney disease in diabetic cases. Clin Exp Nephrol. 2018;22:1046–1051.
   Web of Science ®Google Scholar
• Zhao Z, Liu J, Shi B, et al. Advanced glycation end product (AGE) modified proteins in tears of diabetic patients. Mol Vis. 2010;16:1576–1584.
   PubMed Web of Science ®Google Scholar
• Csősz É, Boross P, Csutak A, et al. Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. J Proteomics. 2012;75:2196–2204.
   PubMed Web of Science ®Google Scholar
• Torok Z, Peto T, Csosz E, et al. Tear fluid proteomics multimarkers for diabetic retinopathy screening. BMC Ophthalmol. 2013;13:40.
   PubMed Web of Science ®Google Scholar
• Li B, Sheng M, Xie L, et al. Tear proteomic analysis of patients with type 2 diabetes and dry eye syndrome by two-dimensional nano-liquid chromatography coupled with tandem mass spectrometry. Invest Ophthalmol Vis Sci. 2014;55:177–186.
   PubMed Web of Science ®Google Scholar
• Pinazo-Durán MD, Zanón-Moreno V, Lleó-Perez A, et al. Genetic systems for a new approach to risk of progression of diabetic retinopathy. Arch Soc Esp Oftalmol. 2016;91:209–216.
   Google Scholar
• Markoulli M, You J, Kim J, et al. Corneal nerve morphology and tear film substance P in diabetes. Optometry Vision Sci. 2017;94:726–731.
   Web of Science ®Google Scholar
• Stuard WL, Titone R, Robertson DM. Tear levels of insulin-like growth factor binding protein 3 correlate with subbasal nerve plexus changes in patients with type 2 diabetes mellitus. Invest Ophthalmol Vis Sci. 2017;58:6105–6112.
   Web of Science ®Google Scholar
• Liu R, Ma B, Gao Y, et al. Tear inflammatory cytokines analysis and clinical correlations in diabetes and nondiabetes with dry eye. Am J Ophthalmol. 2019;200:10–15.
   Web of Science ®Google Scholar
• Tummanapalli SS, Willcox MDP, Issar T, et al. Tear film substance P: a potential biomarker for diabetic peripheral neuropathy. Ocul Surf. 2019;17:690–698.
   PubMed Web of Science ®Google Scholar
• Iyengar MF, Soto LF, Requena D, et al. Tear biomarkers and corneal sensitivity as an indicator of neuropathy in type 2 diabetes. Diabetes Res Clin Pract. 2020;163:108143.
   Web of Science ®Google Scholar
• Stuard WL, Titone R, Robertson DM. Tear levels of IGFBP-3: a potential biomarker for diabetic nerve changes in the cornea. Eye Contact Lens. 2020; 46:319–325.
   Web of Science ®Google Scholar
• Grus FH, Sabuncuo P, Dick HB, et al. Changes in the tear proteins of diabetic patients. BMC Ophthalmol. 2002;2:4.
   PubMedGoogle Scholar
• Lane JD, Krumholz DM, Sack RA, et al. Tear glucose dynamics in diabetes mellitus. Curr Eye Res. 2006;31:895–901.
   PubMed Web of Science ®Google Scholar
• Yu L, Chen X, Qin G, et al. Tear film function in type 2 diabetic patients with retinopathy. Ophthalmol J Int D’ophtalmologie Int J Ophthalmol Zeitschrift Fur Augenheilkunde. 2008;222:284–291.
   Google Scholar
• Liu J, Shi B, He S, et al. Changes to tear cytokines of type 2 diabetic patients with or without retinopathy. Mol Vis. 2010;16:2931–2938.
   PubMed Web of Science ®Google Scholar
• Yang Q, Li B, Sheng M. Meibum lipid composition in type 2 diabetics with dry eye. Exp Eye Res. 2021;206:108522.
   Web of Science ®Google Scholar
• Lewis JG, Stephens PJ. Tear glucose in diabetics. Br J Ophthalmol. 1958;42:754–758.
   Google Scholar
• Sen DK, Sarin GS. Tear glucose levels in normal people and in diabetic patients. Br J Ophthalmol. 1980;64:693–695.
   PubMed Web of Science ®Google Scholar
• Van Haeringen NJ, Glasius E. Collection method dependent concentrations of some metabolites in human tear fluid, with special reference to glucose in hyperglycaemic conditions. Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie. 1977;202:1–7.
   Google Scholar
• Aihara M, Kubota N, Minami T, et al. Association between tear and blood glucose concentrations: random intercept model adjusted with confounders in tear samples negative for occult blood. J Diabetes Investig. 2020; 12:266–276.
   Web of Science ®Google Scholar
• Baca JT, Finegold DN, Asher SA. Tear glucose analysis for the noninvasive detection and monitoring of diabetes mellitus. Ocul Surf. 2007;5:280–293.
   PubMed Web of Science ®Google Scholar
• Liao Y, Yao H, Lingley A, et al. A 3 microW CMOS glucose sensor for wireless contact-lens tear glucose monitoring. IEEE J Solid-State Circuits. 2012;47:335–344.
   Web of Science ®Google Scholar
• Otis B. Update on our smart lens program with alcon. 2018 Nov cited 2021 Jul 8th. Available from: https://blog.verily.com/2018/11/update-on-our-smart-lens-program-with.html
   Google Scholar
• Kim HJ, Kim PK, Yoo HS, et al. Comparison of tear proteins between healthy and early diabetic retinopathy patients. Clin Biochem. 2012;45:60–67.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Kunnen CM, Brown SH, Lazon de la Jara P, et al. Influence of meibomian gland expression methods on human lipid analysis results. Ocul Surf. 2016;14:49–55.
   Web of Science ®Google Scholar
• Brown SH, Kunnen CM, Duchoslav E, et al. A comparison of patient matched meibum and tear lipidomes. Invest Ophthalmol Vis Sci. 2013;54:7417–7424.
   PubMed Web of Science ®Google Scholar
• Khan AR, Awan FR. Metals in the pathogenesis of type 2 diabetes. J Diabetes Metab Disord. 2014;13:16.
   Google Scholar
• Cancarini A, Fostinelli J, Napoli L, et al. Trace elements and diabetes: assessment of levels in tears and serum. Exp Eye Res. 2017;154:47–52.
   Web of Science ®Google Scholar
• Pritchard N, Edwards K, Russell AW, et al. Corneal confocal microscopy predicts 4-year incident peripheral neuropathy in type 1 diabetes. Diabetes Care. 2015;38:671–675.
   PubMed Web of Science ®Google Scholar
• Moschos MM, Rouvas AA, Papadimitriou S, et al. Quantitative determination of glycosaminoglycans in tears of diabetic patients. Clin Ophthalmol. 2008;2:581–584.
   Google Scholar
• Sodhi H, Panitch A. Glycosaminoglycans in tissue engineering: a review. Biomolecules. 2021;11:1–22.
   Web of Science ®Google Scholar
• Lepedda AJ, De Muro P, Capobianco G, et al. Significance of urinary glycosaminoglycans/proteoglycans in the evaluation of type 1 and type 2 diabetes complications. J Diabetes Complications. 2017;31:149–155.
   Web of Science ®Google Scholar
• Costagliola C, Romano V, De Tollis M, et al. TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy. Mediators Inflamm. 2013;2013:629529.
   PubMed Web of Science ®Google Scholar
• Joussen AM, Doehmen S, Le ML, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis. 2009;15:1418–1428.
   PubMed Web of Science ®Google Scholar
• Wei Y, Gadaria-Rathod N, Epstein S, et al. Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures. Invest Ophthalmol Vis Sci. 2013;54:8327–8336.
   PubMed Web of Science ®Google Scholar
• Ang WJ, Zunaina E, Norfadzillah AJ, et al. Evaluation of vascular endothelial growth factor levels in tears and serum among diabetic patients. Plos One. 2019;14:e0221481–e0221481.
   Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–1487.
   PubMed Web of Science ®Google Scholar
• Kawai S, Nakajima T, Hokari S, et al. Apolipoprotein A-I concentration in tears in diabetic retinopathy. Ann Clin Biochem. 2002;39:56–61.
   PubMed Web of Science ®Google Scholar
• Gessl A, Lemmens-Gruber R, Kautzky-Willer A. Thyroid disorders. In: Regitz-Zagrosek V, editor. Sex and gender differences in pharmacology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. p. 361–386.
   Google Scholar
• De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388:906–918.
   PubMed Web of Science ®Google Scholar
• Chaker L, Bianco AC, Jonklaas J, et al. Hypothyroidism. Lancet. 2017;390:1550–1562.
   PubMed Web of Science ®Google Scholar
• Xu N, Cui Y, Fu D, et al. Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids. J Endocrinol Invest. 2020;43:901–910.
   PubMed Web of Science ®Google Scholar
• Song RH, Wang B, Yao QM, et al. Proteomics screening of differentially expressed cytokines in tears of patients with Graves’ ophthalmopathy. Endocr Metab Immune Disord Drug Targets. 2020;20:87–95.
   Web of Science ®Google Scholar
• Chen Q. The expression of interleukin-15 and interleukin-17 in tears and orbital tissues of Graves ophthalmopathy patients. J Cell Biochem. 2019;120:6299–6303.
   PubMed Web of Science ®Google Scholar
• Yang M, Chung Y, Lang S, et al. The tear cytokine profile in patients with active Graves’ orbitopathy. Endocrine. 2018;59:402–409.
   Web of Science ®Google Scholar
• Mandić JJ, Kozmar A, Kusačić-Kuna S, et al. The levels of 12 cytokines and growth factors in tears: hyperthyreosis vs euthyreosis. Graefe’s Arch Clin Exp Ophthalmol. 2018;256:845–852.
   Web of Science ®Google Scholar
• Kishazi E, Dor M, Eperon S, et al. Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy. Sci Rep. 2018;8:10792.
   PubMed Web of Science ®Google Scholar
• Kishazi E, Dor M, Eperon S, et al. Thyroid-associated orbitopathy and tears: a proteomics study. J Proteomics. 2018;170:110–116.
   Web of Science ®Google Scholar
• Choi W, Li Y, Ji YS, et al. Oxidative stress markers in tears of patients with Graves’ orbitopathy and their correlation with clinical activity score. BMC Ophthalmol. 2018;18:303.
   Web of Science ®Google Scholar
• Aass C, Norheim I, Eriksen EF, et al. Establishment of a tear protein biomarker panel differentiating between Graves’ disease with or without orbitopathy. Plos One. 2017;12:e0175274.
   Web of Science ®Google Scholar
• Aass C, Norheim I, Eriksen EF, et al. Comparative proteomic analysis of tear fluid in Graves’ disease with and without orbitopathy. Clin Endocrinol (Oxf). 2016;85:805–812.
   Web of Science ®Google Scholar
• Jiang L, Mou P, Wei R. [Expressions of lysozyme C and lactoferrin in tears of thyroid-associated ophthalmopathy patients]. Zhonghua Yi Xue Za Zhi. 2015;95:749–752.
   Google Scholar
• Huang D, Luo Q, Yang H, et al. Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014;55:4935–4943.
   PubMed Web of Science ®Google Scholar
• Cai K, Wei R. Interleukin-7 expression in tears and orbital tissues of patients with Graves’ ophthalmopathy. Endocrine. 2013;44:140–144.
   Web of Science ®Google Scholar
• Ujhelyi B, Gogolak P, Erdei A, et al. Graves’ orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines. Thyroid. 2012;22:407–414.
   PubMed Web of Science ®Google Scholar
• Matheis N, Okrojek R, Grus FH, et al. Proteomics of tear fluid in thyroid-associated orbitopathy. Thyroid. 2012;22:1039–1045.
   Web of Science ®Google Scholar
• Huang D, Xu N, Song Y, et al. Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy. Graefe’s Arch Clin Exp Ophthalmol. 2012;250:619–625.
   PubMed Web of Science ®Google Scholar
• Yoon JS, Choi SH, Lee JH, et al. Ocular surface inflammation, and nerve growth factor level in tears in active thyroid-associated ophthalmopathy. Graefe’s Arch Clin Exp Ophthalmol. 2010;248:271–276.
   PubMed Web of Science ®Google Scholar
• Baker GR, Morton M, Rajapaska RS, et al. Altered tear composition in smokers and patients with graves ophthalmopathy. Arch Ophthalmol (Chicago, Ill : 1960). 2006;124:1451–1456.
   PubMedGoogle Scholar
• Khalil HA, De Keizer RJ, Bodelier VM, et al. Secretory IgA and lysozyme in tears of patients with Graves’ ophthalmopathy. Documenta Ophthalmologica Adv Ophthalmol. 1989;72:329–334.
   Web of Science ®Google Scholar
• Khalil HA, de Keizer RJ, Kijlstra A. Analysis of tear proteins in Graves’ ophthalmopathy by high performance liquid chromatography. Am J Ophthalmol. 1988;106:186–190.
   PubMed Web of Science ®Google Scholar
• Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9–14.
   PubMed Web of Science ®Google Scholar
• Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31:752–759.
   Google Scholar
• Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11:157–169.
   PubMed Web of Science ®Google Scholar
• Link H, Huang Y-M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol. 2006;180:17–28.
   PubMed Web of Science ®Google Scholar
• Coyle PK, Sibony PA. Tear analysis in multiple sclerosis. Neurology. 1986;36:547–550.
   Web of Science ®Google Scholar
• Devos D, Forzy G, de Seze J, et al. Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis. J Neurol. 2001;248:672–675.
   Web of Science ®Google Scholar
• Calais G, Forzy G, Crinquette C, et al. Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult Scler. 2010;16:87–92.
   PubMed Web of Science ®Google Scholar
• Hümmert MW, Wurster U, Bönig L, et al. Investigation of oligoclonal IgG bands in tear fluid of multiple sclerosis patients. Front Immunol. 2019;10:1110.
   Google Scholar
• Martino G, Servalli C, Filippi M, et al. Absence of oligoclonally restricted immunoglobulins in tears from multiple sclerosis patients. J Neuroimmunol. 1993;44:149–155.
   PubMed Web of Science ®Google Scholar
• Liedtke W, Weller M, Wiethölter H, et al. Immunological abnormalities in the tears of multiple sclerosis patients. Acta Neurol Scand. 1992;85:228–230.
   Web of Science ®Google Scholar
• Cicalini I, Rossi C, Pieragostino D, et al. Integrated lipidomics and metabolomics analysis of tears in multiple sclerosis: an insight into diagnostic potential of lacrimal fluid. Int J Mol Sci. 2019;20:1265.
   Web of Science ®Google Scholar
• Salvisberg C, Tajouri N, Hainard A, et al. Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis. Proteomics Clin Appl. 2014;8:185–194.
   PubMed Web of Science ®Google Scholar
• Hamm-Alvarez SF, Janga SR, Edman MC, et al. Levels of oligomeric α-synuclein in reflex tears distinguish Parkinson’s disease patients from healthy controls. Biomark Med. 2019;13:1447–1457.
   Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VMY, et al. α-synuclein in Lewy bodies. Nature. 1997;388:839–840.
   PubMed Web of Science ®Google Scholar
• Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2:a009399–a009399.
   PubMed Web of Science ®Google Scholar
• Hamm-Alvarez SF, Okamoto CT, Janga SR, et al. Oligomeric α-synuclein is increased in basal tears of Parkinson’s patients. Biomark Med. 2019;13:941–952.
   Web of Science ®Google Scholar
• Maass F, Rikker S, Dambeck V, et al. Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease. Sci Rep. 2020;10:8507.
   Google Scholar
• Çomoğlu SS, Güven H, Acar M, et al. Tear levels of tumor necrosis factor-alpha in patients with Parkinson’s disease. Neurosci Lett. 2013;553:63–67.
   PubMed Web of Science ®Google Scholar
• Boerger M, Funke S, Leha A, et al. Proteomic analysis of tear fluid reveals disease-specific patterns in patients with Parkinson’s disease - A pilot study. Parkinsonism Relat Disord. 2019;63:3–9.
   Web of Science ®Google Scholar
• WHO. Dementia. cited 2021 Jul 8. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
   Google Scholar
• Cennamo G, Montorio D, Morra VB, et al. Surface-enhanced Raman spectroscopy of tears: toward a diagnostic tool for neurodegenerative disease identification. J Biomed Opt. 2020;25:1–12.
   PubMed Web of Science ®Google Scholar
• Shigemoto Y, Sone D, Maikusa N et al. Association of deposition of tau and amyloid-β proteins with structural connectivity changes in cognitively normal older adults and Alzheimer’s disease spectrum patients. Brain Behav. Elsevier; 2018;8:e01145.
   Google Scholar
• Mondragón-Rodríguez S, Perry G, Peña-Ortega F. Chapter 8 - Tau proteins. In: Adejare A, editor. Drug discovery approaches for the treatment of neurodegenerative disorders. Academic Press; 2017. p. 145–160.
   Google Scholar
• O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci. 2011;34:185–204.
   PubMed Web of Science ®Google Scholar
• Twohig D, Nielsen HM. α-synuclein in the pathophysiology of Alzheimer’s disease. Mol Neurodegener. 2019;14:23.
   PubMed Web of Science ®Google Scholar
• Kalló G, Emri M, Varga Z, et al. Changes in the chemical barrier composition of tears in Alzheimer’s disease reveal potential tear diagnostic biomarkers. Plos One. 2016;11:e0158000.
   PubMed Web of Science ®Google Scholar
• Khusro A, Aarti C, Barbabosa-Pliego A, et al. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches. Microb Pathog. 2018;114:80–89.
   Web of Science ®Google Scholar
• Buse DC, Greisman JD, Baigi K, et al. Migraine progression: a systematic review. Headache. 2019;59:306–338.
   PubMed Web of Science ®Google Scholar
• Villalón CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009;124:309–323.
   PubMed Web of Science ®Google Scholar
• Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia. 2019;39:1535–1543.
   PubMed Web of Science ®Google Scholar
• Mohanty D, Lippmann S. CGRP inhibitors for migraine. Innov Clin Neurosci. 2020;17:39–40.
   PubMedGoogle Scholar
• Rentka A, Harsfalvi J, Szucs G, et al. Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis. Immunol Res. 2016;64:619–626.
   Web of Science ®Google Scholar
• Naehrig S, Chao C-M, Naehrlich L. Cystic fibrosis. Dtsch Arztebl Int. 2017;114:564–574.
   Web of Science ®Google Scholar
• Mrugacz M, Kaczmarski M, Bakunowicz-Lazarczyk A, et al. IL-8 and IFN-γ in tear fluid of patients with cystic fibrosis. J Interferon Cytokine Res. 2006;26:71–75.
   PubMed Web of Science ®Google Scholar
• Mrugacz M, Zelazowska B, Bakunowicz-Lazarczyk A, et al. Elevated tear fluid levels of MIP-1alpha in patients with cystic fibrosis. J Interferon Cytokine Res. 2007;27:491–495.
   Web of Science ®Google Scholar
• Bhavsar I, Miller CS, Al-Sabbagh M. Macrophage inflammatory protein-1 alpha (MIP-1 alpha)/CCL3: as a biomarker. In: Preedy VR, Patel VB, editors. General methods in biomarker research and their applications. Dordrecht: Springer Netherlands; 2015. p. 223–249.
   Google Scholar
• Brücher BL, Jamall IS. Epistemology of the origin of cancer: a new paradigm. BMC Cancer. 2014;14:331.
   PubMed Web of Science ®Google Scholar
• Ding D, Han S, Zhang H, et al. Predictive biomarkers of colorectal cancer. Comput Biol Chem. 2019;83:107106.
   PubMed Web of Science ®Google Scholar
• Fabris L, Ceder Y, Chinnaiyan AM, et al. The potential of microRNAs as prostate cancer biomarkers. Eur Urol. 2016;70:312–322.
   PubMed Web of Science ®Google Scholar
• Adhami M, Haghdoost AA, Sadeghi B, et al. Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer. 2018;25:198–205.
   PubMed Web of Science ®Google Scholar
• Das V, Kalita J, Pal M. Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. Biomed Pharmacothe. 2017;87:8–19.
   PubMed Web of Science ®Google Scholar
• Evans V, Vockler C, Friedlander M, et al. Lacryglobin in human tears, a potential marker for cancer. Clin Exp Ophthalmol. 2001;29:161–163.
   PubMed Web of Science ®Google Scholar
• Böhm D, Keller K, Pieter J, et al. Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach. Oncol Rep. 2012;28:429–438.
   PubMed Web of Science ®Google Scholar
• Lebrecht A, Boehm D, Schmidt M, et al. Diagnosis of breast cancer by tear proteomic pattern. Cancer Genomics Proteomics. 2009;6:177–182.
   Google Scholar
• Inubushi S, Kawaguchi H, Mizumoto S, et al. Oncogenic miRNAs identified in tear exosomes from metastatic breast cancer patients. Anticancer Res. 2020;40:3091–3096.
   Web of Science ®Google Scholar